Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-24

Clinical Trial Update: Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics [Phase 3]

View source ↗

Summary

Phase 3 chronic-dose safety and efficacy study of Albuterol-HFA-BAI in pediatric asthmatics completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Albuterol-HFA-BAI (Albuterol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2022-02-24